Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Phenytoin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A known ✓ | P35498 | 1/20 | 0.44 |
| ▸ | SCN4A known ✓ | P35499 | 1/20 | 0.44 |
| ▸ | SCN5A known ✓ | Q14524 | 1/20 | 0.44 |
| ▸ | SCN2A known ✓ | Q99250 | 1/20 | 0.44 |
| ▸ | SCN3A known ✓ | Q9NY46 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.49 |
| ▸ | BLM | P54132 | 2/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7327872 | 0.76 | BACE1 (0.46) | CYP2C9BLMPMP22LMNAGLA | |
| SCHEMBL4782380 | 0.73 | CYP2C9 (0.47) | CYP2C9BLMPMP22LMNAGLA | |
| SCHEMBL11836878 | 0.72 | CYP2C9 (0.50) | CYP2C9BLMPMP22LMNAGLA | |
| SCHEMBL10849988 | 0.71 | ALDH1A1 (0.42) | CYP2C9BLMPMP22LMNAALDH1A1 | |
| SCHEMBL8665106 | 0.71 | ALDH1A1 (0.42) | CYP2C9BLMPMP22ALDH1A1CACNA1F | |
| SCHEMBL17471508 | 0.71 | ALDH1A1 (0.42) | CYP2C9BLMPMP22LMNAKMT2A | |
| SCHEMBL11925189 | 0.68 | GAA (0.48) | CYP2C9BLMPMP22KMT2AALDH1A1 | |
| SCHEMBL2615275 | 0.68 | AKR1B1 (0.43) | CYP2C9BLMPMP22ALDH1A1CACNA1F | |
| SCHEMBL2615278 | 0.68 | AKR1B1 (0.43) | CYP2C9BLMPMP22ALDH1A1CACNA1F | |
| Phenobarbital SCHEMBL42037 | 0.67 | KMT2A (0.50) | CYP2C9BLMPMP22LMNAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382291-A1 | SUBSTITUTED PYRROLO[2,3-b]PYRIDINES FOR SUPPRESSING TOXIC ENDOPLASMIC RETICULUM STRESS | UNIV COLUMBIA (US) | 2025-12-18 | — | — | US | claimed |
| US-20250360081-A1 | ORAL DRUG DOSAGE FORMS FOR STOMACH RETENTION | TRIASTEK INC (CN) | 2025-11-27 | — | — | US | claimed |
| EP-4604932-A1 | ORAL DRUG DOSAGE FORMS FOR STOMACH RETENTION | Triastek, Inc. (CN) | 2025-08-27 | — | — | EP | claimed |
| CN-120076796-A | Oral pharmaceutical dosage form for gastric retention | 南京三迭纪医药科技有限公司 | 2025-05-30 | — | — | CN | claimed |
| WO-2025050066-A1 | COMPOSITIONS INCLUDING SMALL-MOLECULE TERT ACTIVATOR COMPOUNDS AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-03-06 | — | — | WO | claimed |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| US-20240156790-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2024-05-16 | — | — | US | claimed |
| WO-2024083145-A1 | ORAL DRUG DOSAGE FORMS FOR STOMACH RETENTION | Triastek, Inc. (CN) | 2024-04-25 | — | — | WO | claimed |
| EP-4347605-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS | The Trustees of Columbia University in the City of New York (US) | 2024-04-10 | — | — | EP | claimed |
| WO-2023172316-A1 | SELF ALIGNED MULTIPLE PATTERNING METHOD | TOKYO ELECTRON LIMITED (JP) | 2023-09-14 | — | — | WO | claimed |
| US-20230190758-A1 | METHODS OF TREATING CANCER USING NEURONAL ACTIVITY INHIBITING AGENTS | WASHINGTON UNIVERSITY (US) | 2023-06-22 | — | — | US | claimed |
| US-20220380383-A1 | NEUROPROTECTIVE PDI MODULATING SMALL MOLECULES AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2022-12-01 | — | — | US | claimed |
| WO-2022251306-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-12-01 | — | — | WO | claimed |
| WO-2022159506-A1 | DEUTERATED CANNABIDIOL COMPOUNDS | MERIT THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | WO | claimed |
| WO-2022159507-A1 | COMBINATION OF CANNABINOIDS WITH ADDITIONAL THERAPEUTIC AGENTS FOR TREATING DISEASES OR DISORDERS | MERIT THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | WO | claimed |
| US-20260076971-A1 | METHODS OF TREATING EPILEPSY AND REDUCING THE INCIDENCE OF SEIZURES | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260055116-A1 | SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | KARUNA THERAPEUTICS INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-20220106547-A1 | COMPOSITIONS AND METHODS OF USING PARTIAL GEL LAYERS IN A MICROFLUIDIC DEVICE | EMULATE INC (US) | 2022-04-07 | — | — | US | disclosed |
| EP-3965934-A1 | COMPOSITIONS AND METHODS OF USING PARTIAL GEL LAYERS IN A MICROFLUIDIC DEVICE | Emulate, Inc. (US) | 2022-03-16 | — | — | EP | disclosed |
| WO-2022047035-A2 | mRNA Biomarkers for Diagnosis of Liver Disease | HEPGENE, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240156790-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS | AIFM2, GPX1, SLC7A11 | SCN1A 1327/4885SCN4A 2263/4885SCN5A 3385/4885 |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | TACR1, ACHE, TACR2 | SCN1A 1186/4885SCN4A 1884/4885SCN5A 2125/4885 |
| US-20250382291-A1 | SUBSTITUTED PYRROLO[2,3-b]PYRIDINES FOR SUPPRESSING TOXIC ENDOPLASMIC RETICULUM STRESS | HSPA5, ATP2A1, DNAJC10 | SCN1A 2141/4885SCN4A 2816/4885SCN5A 2704/4885 |
| US-20260076971-A1 | METHODS OF TREATING EPILEPSY AND REDUCING THE INCIDENCE OF SEIZURES | JAK1, JAK3, STAT1 | SCN1A 145/4885SCN4A 382/4885SCN5A 529/4885 |
| US-20220380383-A1 | NEUROPROTECTIVE PDI MODULATING SMALL MOLECULES AND METHODS OF USE THEREOF | NLN, PDIA5, PRNP | SCN1A 767/4885SCN4A 1612/4885SCN5A 2117/4885 |
| US-20260055116-A1 | SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | CHRM3, CHRM2, CHRM1 | SCN1A 236/4885SCN4A 342/4885SCN5A 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.